•
PR
PROF
Profound Medical Corp. Common Stock
yahooSURGICAL & MEDICAL INSTRUMENTS & APPARATUS
--
Price Chart
Market Cap
290.34M
Volume
88.90K
52W High
$8.95
52W Low
$3.76
Open
$0.00
Prev Close
$8.00
Day Range
0.00 - 0.00
About Profound Medical Corp. Common Stock
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
Latest News
Profound Medical Corp. Closes $36 Million Registered Direct Offering; Expects to Complete Subsequent Private Placement On or Before December 30th
GlobeNewswire Inc.•Dec 23
Stanford Medicine’s Dr. Pejman Ghanouni Receives RSNA’s Cum Laude Award for CAPTAIN Perioperative Data Presentation
GlobeNewswire Inc.•Dec 4
Profound Named to Redpoint Ventures’ Inaugural AI64 List of the Most Promising AI Companies
GlobeNewswire Inc.•Oct 24
Profound Named to Redpoint Ventures’ Inaugural AI64 List of the Most Promising AI Companies Shaping the Future
GlobeNewswire Inc.•Oct 24
High Intensity Focused Ultrasound (HIFU) Market to Reach $1.81 Billion by 2034, Growing at a CAGR of 10.4% | Rising Demand for Non-Invasive Therapeutic Solutions Driving Global Market Expansion
GlobeNewswire Inc.•Apr 16
Wolf Haldenstein Adler Freeman & Herz LLP is investigating Profound Medical Corp. for potential violations of securities laws
GlobeNewswire Inc.•Mar 27
Profound Medical to Release Fourth Quarter and Full Year 2024 Financial Results on March 6 – Conference Call to Follow
GlobeNewswire Inc.•Feb 13
Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2024 Revenues
Benzinga•Jan 8